| Expression pattern: |
UP |
| Associated gene: |
TK1, Bax, cleaved caspase-3, Bcl-2, MRP1, MDR1, gamma-H2A.X |
| Associated microRNA: |
miR-885-3p |
| Biological function: |
Promotes LUAD cell proliferation, migration, invasion, tumor growth and cisplatin chemoresistance; inhibits apoptosis, cell cycle arrest and DNA damage. |
| Molecular mechanism: |
ceRNA mechanism through direct binding to miR-885-3p and positive regulation of TK1 expression, modulating DNA damage and apoptosis pathways. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); cell cycle (promotes); drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (other); other pathway/process (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; TUNEL; IHC (Immunohistochemistry); Western Blot; In Vivo Animal Model; ROC Analysis; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circ_IGF2BP1 has potential diagnostic value in distinguishing LUAD tissues from adjacent non-tumor tissues, is significantly correlated with T stage, and may serve as a potential diagnostic and prognostic biomarker in NSCLC; Kaplan-Meier analysis did not show a significant association with overall survival in the limited follow-up cohort. |
| Description: |
circ_IGF2BP1 is a human IGF2BP1-derived circular RNA up-regulated in LUAD/NSCLC tissues and LUAD cell lines. It promotes malignant phenotypes and cisplatin resistance by acting as a ceRNA for miR-885-3p, thereby positively regulating TK1 and modulating DNA damage and apoptosis-related pathways. Clinically, its expression shows diagnostic potential and association with T stage, but no significant overall survival association was observed in the limited follow-up cohort. |
| Confidence score: |
0.8425 |